It does not receive public funding
Editor in chief:
CLARA MOSCHINI

Facebook Twitter Youtube Instagram LinkedIn

European Parliament. Question on Covid-19 and delays in vaccine deliveries

Presented by eight MEPs of PPE

"Parliamentary questions

22 January 2021 E-000398/2021

Question for written answer E-000398/2021 to the Commission

Rule 138 Silvio Berlusconi (PPE), Antonio Tajani (PPE), Salvatore De Meo (PPE), Herbert Dorfmann (PPE), Fulvio Martusciello (PPE), Giuseppe Milazzo (PPE), Aldo Patriciello (PPE), Massimiliano Salini (PPE) 

Subject: COVID-19 – Delays in vaccine deliveries

As part of the EU’s strategy to speed up the development, production and distribution of safe and effective COVID-19 vaccines, the Commission has financed research into vaccines through subsidies to some private pharmaceutical concerns, negotiating the cost per vaccine dose and supervising the supply thereof.

The US firm Pfizer has cut the supply of vaccines Italy was expecting to receive right now by around 30 % of the quantities agreed, without giving any prior notice. Other EU countries are experiencing the same problem.

The contract signed by the Commission with the vaccine manufacturers stipulates a uniform supply of vaccines and that notice of any alterations must be given well in advance; the aforesaid reduction in supply puts the efficiency of the vaccine plan at risk.

In light of the above:

1 Does the Commission know what is happening in Italy and the rest of the EU? If so, is it going to ascertain whether Pfizer has failed to abide by the contract terms?

2 Will it disclose which clauses in the contract fix the quantities and time frames for distribution of the vaccines, and what penalties have been provided for, if necessary?

3 What steps will it take to avoid shortfalls in the distribution of vaccine doses?

Last updated: 3 February 2021".

red - 1234667

AVIONEWS - World Aeronautical Press Agency
Similar